Tekmira suspends Ebola work; changes name, focus
This article was originally published in Scrip
Once one of the hottest Ebola firms investors couldn't get enough of, Tekmira on 20 July said it was suspending its drug development activities in the space and focusing its efforts on hepatitis B virus (HBV) – even changing its company name to Arbutus Biopharma, effective 3 August.
You may also be interested in...
Among the topics at the European liver meeting was whether reducing HBV surface antigen might be part of a combination approach to curing chronic hepatitis B. One of the leaders in this approach, Arbutus, is working toward its own internal combo therapy for the virus.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.